MetaCap

Biohaven (BHVN) vs Maravai LifeSciences (MRVI)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Maravai LifeSciences (MRVI) has outperformed Biohaven (BHVN) over the past year, gaining 86.1% versus a gain of 27.9%. Biohaven is the larger company by market cap ($1.87 billion vs $1.81 billion), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BHVN+27.86%MRVI+86.13%
+148%+58%-33%
Nov 21, 20251 yearNov 20, 2026
BHVN+73.63%MRVI-72.97%
+753%+310%-133%
Sep 19, 20225 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BHVN versus MRVI key metrics
MetricBHVNMRVI
Share price$12.39$6.98
Market cap$1.87B$1.81B
1-day change-9.23%-2.92%
YTD return+9.74%+114.77%
1-year return+27.86%+86.13%
5-year return—-83.18%
EPS (TTM)$-3.77$-0.44
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$185.74M
Revenue growth (YoY)—-28.34%
Net income (latest FY)$-738.82M$-130.77M
Gross margin—18.30%
Operating margin—-115.89%
Net margin—-70.41%
52-week high$18.24$9.42
52-week low$8.03$2.80
Distance from 52-week high-32.07%-25.90%
Analyst consensusbuybuy
Avg. price target upside+102.82%+38.11%
Average volume3.24M2.72M
Shares outstanding151.06M149.25M
Employees274410
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • MRVI has outperformed BHVN by 58.3 percentage points over the past year.

About Biohaven

BHVN stock →

Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity.

Health Care · Biotechnology: Pharmaceutical Preparations · 274 employees

About Maravai LifeSciences

MRVI stock →

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America. It operates through two segments: TRILINK and CYGNUS.

Health Care · Biotechnology: Pharmaceutical Preparations · 410 employees

BHVN vs MRVI FAQ

Which is bigger, Biohaven or Maravai LifeSciences?

Biohaven (BHVN) is larger, with a market capitalization of $1.87B compared with $1.81B for Maravai LifeSciences (MRVI).

Which stock has performed better over the past year, BHVN or MRVI?

MRVI returned +86.13% over the past 12 months, compared with +27.86% for BHVN (price return, excluding dividends). Past performance does not predict future results.

Are Biohaven and Maravai LifeSciences in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons